Navigation Links
INTERCIM Received a New Patent for a Non-statistical Approach for "Design of Experiments" and the Iterative Discovery of an Explanatory Model
Date:10/6/2010

INTERCIM Received a New Patent for a Non-statistical Approach... -- ST. PAUL, Minnesota and PARIS, October 6, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Internet Technology, Computer Electronics, Computer Software, Biotechnology, Medical Pharmaceuticals, New Products & Services Click to view news release full screen  

INTERCIM Received a New Patent for a Non-statistical Approach for "Design of Experiments" and the Iterative Discovery of an Explanatory Model

   

Company Awarded Patent # 7,617,171 B2

ST. PAUL, Minnesota and PARIS, October 6, 2010 /PRNewswire/ -- Intercim, LLC, a global leader in manufacturing operation management (MOM) software, announced it has been awarded a patent called "Process for the iterative construction of an explanatory model".

This patented process is a key component of the Intercim Operations Intelligence technology and will help industrial manufacturers and life sciences researchers in two ways: unlike a statistics-based approach, it reuses existing information to optimize the length and cost of an experiment plan and it gives a quick and effective way to confirm the reliability of a discovery with only a few experiments.

This approach enables Pertinence Suite's users to get, much faster, a more reliable explanatory model even with limited data points available in a highly multi-dimensional non-euclidian space.

"This approach seems much easier to adopt than other standard Design of Experiment techniques, because we can analyze simultaneously the influence of many design parameters without statistical hypotheses. Thanks to the Interactive Experiment Planning of Process Rule Discovery(TM), we have reduced our need for physical experiments by 50% and sometimes more," says Dominique Veret, former Head of Development at Siemens Automotive Hydraulics, now Continental.

In the last 18 months, Intercim has received several additional patents which validate the uniqueness of Intercim's logic-based analytics for rule discovery and rule-based real-time predictions on complex systems and industrial processes. The announcement of this latest patent further demonstrates the unprecedented value proposition that Intercim offers to the market in terms of Operations Intelligence. John Todd, Intercim's CEO adds, "This patent confirms that Intercim truly offers a unique and high value-add capability. This latest Patent award helps validate Intercim's contribution to improved complex system understanding, manufacturing productivity and cycle time optimization for our key markets: Aerospace & Defense, Automotive and Life Sciences."

About Intercim

Intercim has a 27-year history of helping advanced and highly regulated manufacturers reach their business goals through best in class software solutions. Early 2009, Dassault Systemes a world leader Product Lifecycle Management took a minority position in Intercim. For the first time, the combination of Intercim's software capabilities with the virtual experience provided by Dassault Systemes' solutions allows this type of mission-critical collaboration and knowledge sharing. Intercim serves industry-leading customers such as Boeing, EADS, Areva, Intel, Sanofi-Pasteur, BMW, and Honeywell.


'/>"/>
SOURCE Intercim
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ITGI Medical Received a CE Mark for its Second Pericardium Covered Stent - AneuGraft(R) - for Tortuous Vessels
2. MIT is pleased to announce that it has received a US$ 500,000 private placement from its Chinese partners
3. MIT is pleased to announce that it has received clearance by FINRA to be listed on the OTC Bulletin Board "MDLH.OB"
4. MADIT-CRT Trial Data Show Women Received Greater Benefit From CRT-Ds Than Men
5. Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma
6. Bion Announces Approval of New U.S. Patent for Phosphorus Removal Process for Livestock Waste Environmental Treatment
7. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
8. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
9. Ortho-McNeil Neurologics to Appeal Patent Ruling on RAZADYNE(R)
10. PSKW Expands Its Lawsuit Against McKesson to Seek Assignment of McKessons Patent Application
11. Purdue Pharma L.P. Announces Resolution of OxyContin(R) Patent Lawsuit with Mallinckrodt Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016  OncoSec Medical Incorporated ("OncoSec") ... DNA-based intratumoral cancer immunotherapies, today announced financial results ... "We are delivering on our commitment to ... ImmunoPulse® IL-12. We are pleased with the early ... trial, and we are focused on advancing our ...
(Date:12/8/2016)...  Renova™ Therapeutics, a biotechnology company developing gene ... 2 diabetes, announced that it has obtained a ... vector developed in the laboratory of Professor ... The company plans to use this vector in ... "Early research has shown promise ...
(Date:12/8/2016)... Oxford Gene Technology ... Palette an anpassbaren SureSeq™ NGS-Panels mit dem Start ... ein schnelles und kostengünstiges Studium der Varianten bei ... Erkennung von Einzel-Nukleotid-Variationen (Single Nucleotide Variation, SNV) und ... Panel und ermöglicht eine individuelle Anpassung durch die ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... commercial launch of flexible packaging for their exceptionally efficient human mesenchymal stem/stromal ... extends RoosterBio’s portfolio of bioprocess media products engineered to radically streamline culture ...
Breaking Biology Technology:
(Date:12/7/2016)... , Dec. 7, 2016   Avanade ... successful Formula One teams in history, exploit biometric data ... stop performance and maintain the competitive edge against their ... 2016. Avanade has worked with Williams ... range of biometric data (heart rate, breathing rate, temperature ...
(Date:12/6/2016)... RALEIGH, N.C. , Dec. 6, 2016 ... technology, announced today it has seen a third consecutive ... biometric sensor technology in 2016 with a 360 ... over last year. This increase was driven by sales ... well as robust interest in its technology for hearables ...
(Date:12/2/2016)... , December 1, 2016 ... type (Fingerprint, Voice), Future Technology (Iris Recognition System), ... Region - Global Forecast to 2021", published by ... 442.7 Million in 2016, and is projected to ... a CAGR of 14.06%.      (Logo: ...
Breaking Biology News(10 mins):